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Abstract 
Background: Limited evidence suggests that rizatriptan given before vestibular stimulation 
reduces motion sickness in persons with migraine-related dizziness. The present study was 
designed to test whether rizatriptan is also effective in protecting against visually-induced 
motion sickness and to test whether rizatriptan blocks the augmentation of motion sickness 
by head pain.   
Material and Methods: Using randomized double-blind, placebo-controlled methodology, 
10 females, 6 with migrainous vertigo (V+) and four without vertigo (V-) received 10 mg ri-
zatriptan or placebo two hours prior to being stimulated by optokinetic stripes. Visual 
stimulation was coupled with three pain conditions: no pain (N), thermally-induced hand 
pain (H) and temple pain (T). Motion sickness and subjective discomfort were measured. 
Results: Motion sickness was less after pre-treatment with rizatriptan for 4 of 10 subjects 
and more for 5 of 10 subjects. Augmentation of motion sickness by head pain was seen in 6 
of 10 subjects; this effect was blunted by rizatriptan in 4 of these 6 subjects. Subjective dis-
comfort was significantly more noticeable in V+ subjects as compared with V- subjects. 
Conclusions: These pilot data suggest that rizatriptan does not consistently reduce visu-
ally-induced motion sickness in migraineurs. Rizatriptan may diminish motion sickness po-
tentiation by cranial pain. 
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Introduction 
Migrainous vertigo is accepted as a common 
cause of episodic vertigo, affecting about 1% of the 
population  1. A recent survey comparing the occur-
rence of vestibular complaints in 327 migraine pa-
tients and 324 controls without frequent headache 
reported dizziness or vertigo in 52% of migraine pa-
tients versus 32% of controls (P<0.0001)  2. Further-
more, 23% of those migraine patients with vestibular 
complaints met criteria for the diagnosis of migrain-
ous vertigo. Patients with migraine with aura had 
significantly more migraine attacks associated with 
vestibular complaints always (15% vs. 10%) or some-
times (22% vs. 5%) (P<0.0001). 
Vestibular abnormalities have been identified in 
migraineurs when asymptomatic between headache 
episodes. A small study comparing interictal vesti-
bular function in individuals with migraine with and 
without vertigo and controls (N=15) showed reduc-
t i o n  i n  m e a n  g a i n  o f  t h e  s e m i c i r c u l a r  c a n a l - o c u l a r  
reflex, a larger modulation component of the oto-
lith-ocular reflex, and increased postural sway during 




vertigo  3. Recently, a larger study similarly testing 
vestibular function in patients with migraine or con-
trols (N=75) identified saccadic pursuit, unilateral 
caloric hypofunction, and increased sway velocity on 
posturography in individuals with migrainous ver-
tigo 4. Others have failed to differentiate migraineurs 
with and without vertigo, based on specialized ves-
tibular testing 5, 6. 
Motion sickness provides an easily reproduced 
vestibular symptom. Motion sickness can be induced 
by stimulation of the vestibular receptors via actual 
motion or motion of visual surroundings, such as 
optokinetic stimuli. Such visually-induced motion 
sickness is often accompanied by a sensation of self 
motion indistinguishable from sensations experienced 
during actual motion. Visually-induced motion sick-
ness can be as severe as that induced by actual mo-
tion. Drummond reported motion sickness symptoms 
after exposure to individual motions (e.g., boat, car, or 
amusement park rides) in 30-40% of migraineurs, 
with motion sickness after viewing visual stimuli 
(e.g., simulators or movie screens) in about 20-30% 7. 
Interestingly, motion sickness induced by actual mo-
tion did not predict motion sickness from visual 
stimuli. Research by Drummond and Granston 
showed that visually-induced motion sickness in mi-
graineurs can be potentiated by combining head pain 
with a provocative visual stimulus 8. 
Reducing motion sickness can be accomplished 
by avoidance of a provocative stimulation or using 
vestibular suppressants. Triptans have been incon-
sistently shown to decrease symptoms in patients 
diagnosed with migrainous vertigo 9, 10. A recent case 
report of three women with migrainous vertigo noted 
head pain induction or aggravation with resolution of 
vertigo after triptan treatment (sumatriptan in 2 pa-
tients and rizatriptan in one patient) of usual vertigo 
attacks  11. Our previous research has suggested in a 
small pilot study that rizatriptan, when given orally 
two hours prior to exposure to a complex vestibular 
stimulation, reduces motion sickness in persons with 
migraine-related dizziness 12. Based upon this ap-
parent protective effect of rizatriptan for motion 
sickness induced by actual motion in migraineurs, we 
embarked upon a comparable study of visu-
ally-induced motion sickness. We were especially 
interested in replicating and extending research by 
Drummond and Granston 8 that showed that visu-
ally-induced motion sickness in migraineurs can be 
potentiated by combining head pain with a provoca-
tive visual stimulus, the “Drummond Effect”. In the 
present study, using a small number of subjects, we 
addressed the hypotheses that rizatriptan acts as a 
protective agent against visually-induced motion 
sickness in migraineurs and that rizatriptan interferes 
with the Drummond Effect.  
Methods 
This double-blind placebo controlled pilot study 
compared the development of visually-induced mo-
tion sickness after pre-treatment with a typical mi-
graine dose of the serotonin agonist rizatriptan or 
placebo. Rizatriptan was selected for this study based 
upon its superior ability to cross the blood-brain bar-
rier 13. This trial was conducted in accordance with the 
guidelines of the International Conference on Har-
monization for Good Clinical Practice and the study 
protocol was approved by a local Institutional Review 
Board. Each study participant provided informed 
consent prior to study enrollment. 
For this pilot study, data from ten females with 
migraine headache and a history of motion sickness 
are reported. Eligible subjects were identified via local 
paid advertisements. Subjects were required to be 
21-45 years old with a diagnosis of ICHD-II migraine 
with or without aura 14. Subjects were initially 
screened by telephone for migraine using the previ-
ously-validated Migraine Assessment Tool 15, with the 
diagnosis confirmed through clinical evaluation by a 
board-certified neurologist. Eligible subjects were 
required to report a typical migraine frequency of at 
least 2 episodes per month and have previously 
demonstrated tolerability to any triptan medication. 
Subjects were also required to report a history of mo-
tion sickness symptoms with actual or visu-
ally-induced motion. Subjects were excluded if they 
had heart disease, uncontrolled hypertension, a fam-
ily history of early myocardial infarction, were current 
smokers, or were pregnant. Subjects were also ex-
cluded if they had neurologic or otologic disease aside 
from migraine or migraine-related dizziness or a di-
agnosis of hemiplegic or basilar migraine. Subject 
candidates were subsequently evaluated by a neu-
rotologist using the validated Structured Interview for 
Migrainous Vertigo 16 and clinical assessment to 
categorize subjects as having migraine with (V+) or 
without (V-) migrainous vertigo, based on previously 
published criteria by Neuhauser, et al. 17. 
During the screening visit, subject candidates 
were evaluated with testing of visual and auditory 
acuity, along with vestibular screening tests. Eye po-
sition data were collected using infrared cameras 
housed in form-fitted goggles for the following tests: 
ocular motor screen, gaze and spontaneous nystag-
mus search, positional nystagmus search, caloric irri-
gation, and earth vertical axis rotational testing. Dur-
ing ocular motor screening, subjects were placed in 




were projected. Subjects were instructed to watch the 
laser target as it moved in different patterns or count 
stripes as they moved in a clockwise or counter-
clockwise manner. For gaze and spontaneous nys-
tagmus search, subjects were asked to look straight 
ahead and then left, right, up, and down for 10-15 
seconds in each position. The testing was repeated 
with and without visual fixation. Positional nystag-
mus assessed using infrared goggles with eyes open 
in darkness. Subjects were asked to recline in the su-
pine position, then with head turned right and left 
and finally on his/her right side and then left side. 
Each position was held approximately 20 seconds. 
Caloric irrigation was performed using a closed-loop 
irrigator with the ear stimulated with water at 30° and 
44°C. Both temperatures were performed in each ear. 
Subjects were asked to count by 2’s for 40 seconds 
after irrigation completion to keep from suppressing 
the vestibular response. For earth vertical axis rota-
tional testing, subjects were rotated sinusoidally in the 
dark with frequencies varying from 0.02 to 1.0 Hz and 
amplitudes of 25 to 150 degrees/second and constant 
velocity of 60 degrees/second. Subjects were ex-
cluded if, on baseline screening, they had corrected 
vision worse than 20/40 in each eye or abnormalities 
on clinical audio-vestibular laboratory testing.  
Eligible candidates were then scheduled to re-
turn for two experimental visits, scheduled at least 
one week apart. Subjects were required to have been 
without any headache for 48 hours prior to each test-
ing visit and have not used any triptan for at least 1 
week prior to each experimental visit. Vital signs were 
recorded and then subjects were treated orally in a 
blinded fashion with either 10 mg of rizatriptan (R) or 
a placebo (P) in identical capsules two hours prior to 
exposure to optokinetic stripes. Each subject received 
R on one testing day and P on the other. The order of 
treatment was determined randomly by the inde-
pendent pharmacists, who created the randomization 
scheme by drawing treatment assignments from a 
blinded container. The investigator administering the 
drug, the technicians performing testing, and the 
subject were blinded to treatment assignment. The 
Investigational Drug Service provided the unidenti-
fiable drug in a container labeled only with the visit 
number. The randomization scheme was not un-
blinded until the data were collected for the entire 
study. Blood pressure, heart rate, and the develop-
ment of any adverse events were monitored for the 
two hours after ingestion of study drug. Two hours 
was selected as the optimal time for exposure to a 
potentially motion-sickness provoking stimulus so 
that rizatriptan could obtain its peak mi-
graine-relieving effect 18.  
Two hours after study-drug administration, 
subjects were exposed to three 15-minute trials of 
full-field optokinetic stripes rotated horizontally us-
ing a constant velocity of 30 degrees/second. Either 
clockwise or counterclockwise motion was used for 
all trials for each subject. Testing was identical on both 
experimental days. Prior to visual stimulation, sub-
jects were assessed using the Motion Sickness Scale 
(MSS)  19 to establish a baseline. Subjective Units of 
Discomfort (SUDs) also were assessed. The MSS in-
cludes assessments of nausea, skin color, cold sweat-
ing, increased salivation, drowsiness, headache, and 
dizziness with eyes open and closed. Severity of ab-
normalities in each category are rated by the subject 
and technician, with a range of scores for nausea of 0 
to 16, for skin color of 0 to 8, for cold sweating of 0 to 
8, salivation of 0 to 8, drowsiness of 0 to 8, and head-
ache and dizziness as described below. If MSS ex-
ceeded 16 at any time, the trial was discontinued. 
SUDs rates anxiety from 0 (none) to 10 (panic level 
anxiety). MSS and SUDs, recorded approximately 
every 2 minutes during and after exposure. On each 
day of testing, subjects were exposed to three different 
pain conditions presented in random order that were 
coupled with the optokinetic visual stimulation: no 
pain (N), hand pain (H), and temple pain (T). During 
the N condition, subjects viewed rotating vertical 
black and white stripes projected onto a wall. Every 2 
minutes during the N trial, subjects were asked to rate 
their motion sickness and anxiety. During the H con-
dition, 2 minutes after beginning stripe viewing, the 
subject’s non-dominant hand was immersed in 32ºC 
water for 2 minutes then immersed in 2ºC ice water 
for 30 seconds and then back into the warm bath. Ice 
water immersion was repeated at 8 and 12 minutes, 
with subjects rating motion sickness and anxiety 
throughout. During T, subjects were asked to place a 
small block of ice at their temple using a gloved hand 
for 30 seconds, starting 4 minutes after stripe viewing. 
Subjects were asked to select that side of the head that 
was most commonly affected with pain during a mi-
graine. Ice to the temple was repeated at 8 and 12 
minutes. Subjects rated their motion sickness and 
anxiety throughout. The order of pain conditions was 
assigned to each subject randomly, with at least 2 
minutes of rest time between trials. Testing was dis-
continued at the subject’s request or if the MSS 
reached 16 or above. 
Data analysis 
The overall motion sickness score for each pain 
condition was determined by subtracting the MSS 
score obtained just prior to exposure to the optoki-




age MSS score obtained during and 2 minutes after 
the 15-minute exposure. Overall SUDs for each pain 
condition was determined by subtracting the SUDs 
score obtained just prior to exposure to the optoki-
netic stimulus for that pain condition from the aver-
age SUDs score obtained during and 2 minutes after 
the 15-minute exposure. 
Comparisons between pain conditions and be-
tween testing sessions within each subject were 
evaluated using non-parametric analyses. Compari-
sons between V+ and V- groups and between groups 
with and without visual motion sensitivity were per-
formed using the Wilcoxon rank sum test.  
Results 
Fourteen persons were identified as possible 
study candidates. Of these, one was excluded because 
of abnormal baseline caloric responses, one was ex-
cluded due to technical reasons, and two subjects 
withdrew prior to completing the study. The 10 sub-
jects completing the study were all female, ranging in 
age from 25 to 42 years old (mean 34.6 +/- 6.9 years). 
(See Table 1.) Six subjects met Neuhauser criteria for 
migraine-related vertigo (V+) and four had no com-
plaints of vertigo (V-). Each of the ten subjects toler-
ated the experimental procedures well and had no 
adverse effects from the drug or the induction of pain. 
There were no changes in heart rate or blood pressure 
that required discontinuation of an experiment. Three 
trials were terminated early because MSS exceeded 
16. 
Motion sickness induced by moving optokinetic 
stripes was higher on average during placebo trials 
than during rizatriptan trials in 4 of 10 subjects, higher 
with rizatriptan in 5 of 10 subjects, and unchanged for 
one subject. Motion sickness was not different be-
tween the V+ group and the V- group based on the 
Wilcoxon rank-sum test. Motion sickness was higher 
for the T condition than for the H condition for 6 of 10 
subjects for placebo trials. For these 6 subjects, 4 of 
them showed a decreased or absent Drummond Effect 
with rizatriptan. That is, rizatriptan interfered with 
the potentiation of motion sickness symptoms by 
concomitant temple pain in 4 of 6 subjects. This effect 
of rizatriptan was equally apparent in the V+ group 
and V- groups. Motion sickness was not different 
between those subjects with a history of visu-
ally-induced motion sickness vs. those subjects with-
out a history of visually-induced motion sickness us-
ing the Wilcoxon rank-sum test.  
Data regarding the amount of anxiety induced 
by the combinations of pain and visual motion based 
on SUDs indicated that during testing following in-
gestion of rizatriptan the V+ group was more anxious 
overall than the V- group (p<.05) based on the Wil-
coxon rank-sum test. Rizatriptan did not appear to 
consistently either reduce or increase anxiety during 
testing. 
 
Table 1. Demographics of the subject group. 
Motion Sickness History Subject Num-
ber 
Age Gender  Aura/No  Aura  Diagnosis 
Actual Visual 
Prior headache response to triptan 
1  32 Female Aura  Vertigo  x    Sumatriptan  –  benefit   
2  39 Female No  Aura  Vertigo  x  x  Sumatriptan  –  benefit   
3  37 Female Aura  Non-Vertigo  x  x  Rizatriptan,  Sumatriptan,  Eletriptan  –  no 
benefit 
Frovatriptan – benefit 
4  23  Female  Aura  Vertigo  x    Sumatriptan – no benefit; Rizatriptan- benefit
5  40 Female Aura  Vertigo  x    Sumatriptan  –  benefit 
6  29  Female  No Aura  Non-Vertigo  x  x  Zolmitriptan – no benefit; Eletriptan – benefit
7  41  Female  Aura  Non-Vertigo  x    Sumatriptan, Rizatripitan (benefit unknown) 
8  43 Female Aura  Vertigo    x  Sumatriptan  –  benefit; 
9  26 Female Aura  Vertigo  x    Frovatriptan  –  benefit 




Our initial pilot study regarding the effect of 
triptans on motion sickness combined actual motion, 
i.e., vestibular stimulation, with rizatriptan 12. That 
study suggested a possible protective effect of a sero-
tonin agonist for motion sickness in migraineurs with 
migraine-related dizziness. The pilot study reported 
herein extends this line of research by combining a 
visual motion sickness-inducing stimulus with pain 
and pre-treatment with rizatriptan. In this study, ri-
zatriptan does not appear to reduce visually-induced 
motion sickness but rizatriptan may reuce the poten-
tiation of motion sickness by cranial pain. This effect 
does not appear to be greater in subjects with mi-




may interfere with a previously recognized phe-
nomenon wherein laboratory-induced head pain but 
not extremity pain potentiates visually-induced mo-
tion sickness in migraineurs, i.e., the Drummond Ef-
fect  8. The exact mechanism whereby rizatriptan in-
terferes with the Drummond Effect is uncertain. Ri-
zatriptan may interfere with connections between 
central pain pathways and the vestibular nuclei. 
Motion sickness is a behavioral response to both 
self-motion and visually-induced motion that has no 
known purpose 20. Motion sickness is especially 
common in migraineurs 21, 22, occurring with a fre-
quency of about 50% 23. This increased susceptibility 
to motion sickness in migraineurs is of uncertain 
cause and can occur with both self motion, i.e., vesti-
bular-induced motion sickness, and with visual mo-
tion, i.e., visually-induced motion sickness. We have 
theorized previously that increased activity in vesti-
bulo-autonomic projections, possibly via serotonin, 
may account for increased symptoms in migraineurs 
24, 25 Recently, an alternate theory of motion sickness 
has been developed that links motion sickness to al-
terations in the so called “velocity storage” portion of 
the central vestibular system 26, 27. Interestingly, al-
though velocity storage appears to be unchanged in 
patients with migraine, our previous studies 3, 12 
showed that both motion sickness and velocity stor-
age decreased with rizatriptan. 
Rizatriptan is known to influence the central 
nervous system 13, 28 and in particular, rizatriptan 
probably influences the vestibular nuclei since sero-
tonin receptors have been found in the vestibular nu-
clei 29 and serotonin influences the activity of neurons 
in the vestibular nuclei 30. Vestibulo-autonomic 
pathways 20 may be especially sensitive to rizatriptan 
in that rizatriptan is known to decrease nausea in mi-
graine 31 but also may have a side effect of dizziness 32, 
33. Also, serotonin agonists have been shown to de-
crease emesis in animal models 34-36 and tryptophan 
depletion has been found to increase visually-induced 
nausea and dizziness in migraineurs 7. Based on our 
results and the known effects of rizatriptan and sero-
tonin, we hypothesize that rizatriptan provides bene-
fit regarding motion sickness in some migraineurs by 
influencing central vestibulo-autonomic pathways 
both directly and indirectly. 
Our subjects’ anxiety, as reflected by subjective 
discomfort, was greater in the subjects with migrain-
ous vertigo. This finding is consistent with the exces-
sive vestibular symptoms in this group. Possibly, this 
finding is based on enhanced activity in the circuitry 
linking the vestibular nuclei to more rostral structures 
such as the parabrachial nucleus37.  
Although not uniformly successful, this pilot 
study provides additional impetus for the possibility 
of using triptans for prophylaxis against motion 
sickness, especially in those migraineurs who have 
dizziness associated with headache. The current 
treatment for motion sickness includes scopolamine 
as a prophylaxis agent 38. To date, there is no literature 
aside from our pilot studies that suggest using a trip-
tan for motion sickness prophylaxis.  
Limitations of this study include the small 
number of subjects and the inclusion of only females. 
The gender inequality may have been less important 
given the finding by Park and Hu 39 that there was no 
gender difference for visually-induced nystagmus. 
Our sample also may be atypical of clinical samples of 
migraineurs given the high number of V+ subjects 
identified. Although Neuhuaser identified V+ in only 
9% of migraineurs 17, a migraine sample recruited at 
our center for a previously reported study found V+ 
in 41% of adult migraineurs self-selecting to partici-
pate in a research study 16. Future research in this area 
should include a larger number of subjects. Also, it 
may be of interest to assess motion sickness prophy-
laxis in migraineurs using a CGRP antagonist 40, when 
these agents become more widely available. 
Conclusions 
These pilot data suggest that rizatriptan may in-
terfere with the potentiation of visually-induced mo-
tion sickness in migraineurs by cranial pain. Ri-
zatriptan did not appear to alter visually-induced 
motion sickness overall nor did rizatriptan alter sub-
jective discomfort. Subjects with migrainous vertigo 
exhibited more discomfort during induction of visu-
ally-induced motion sickness. 
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